Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054).

MLA

Peiperl, Laurence, et al. “Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054).” PLoS ONE, vol. 5, no. 10, Oct. 2010, pp. 1–15. EBSCOhost, https://doi.org/10.1371/journal.pone.0013579.

APA

Peiperl, L., Morgan, C., Moodie, Z., Hongli Li, Russell, N., Graham, B. S., Tomaras, G. D., De Rosa, S. C., & McElrath, M. J. (2010). Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). PLoS ONE, 5(10), 1–15. https://doi.org/10.1371/journal.pone.0013579

Chicago

Peiperl, Laurence, Cecilia Morgan, Zoe Moodie, Hongli Li, Nina Russell, Barney S. Graham, Georgia D. Tomaras, Stephen C. De Rosa, and M. Juliana McElrath. 2010. “Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054).” PLoS ONE 5 (10): 1–15. doi:10.1371/journal.pone.0013579.